Pediatric PRV Dashboard

Enter your 6-digit access code

Home | Rare Pediatric Tumors | Oncology Deals | PRV Vouchers

Pediatric Priority Review Voucher (PRV) Dashboard

Market intelligence & legislative tracking · Updated March 14, 2026

Explore PRV Knowledge Graph
Total PRVs Awarded
63
Record 11 in 2024 alone
Diseases Treated
47
43 had no prior treatment
Latest Sale Price
$160M
Bavarian Nordic, Jun 2025
Program Expires
Sep 2029
Reauthorized Feb 3, 2026
DOGE Impact on FDA
19% Staff Cut
H2 2025 on-time approvals dropped to 78% (vs. 85-90% historical). First DOGE-caused review delay in June 2025. Capacity risks growing into 2026.
CNPV Program (new)
15 Issued / 3 Approved
Launched Jun 2025. Ultra-fast 30-60 day review. Non-transferable (cannot be sold). 4 recipients signed MFN pricing deals.
PRV Sale Prices Over Time ($M)
Price Distribution by Era
Recent Transactions: Seller & Price
Abolishment Probability Assessment
PRVs Awarded Per Year
FDA On-Time Approval Rate (%)
Legislative Timeline (2024-2026)
December 20, 2024
Program lapsed. FDA's authority to grant new RPD designations expired.
September 17, 2025
House Committee markup of the Give Kids a Chance Act of 2025.
December 1, 2025
House passed Give Kids a Chance Act (H.R. 1262 / S. 932).
December 17, 2025
Senate unanimous consent failed due to disagreements over bundled health program reauthorizations.
Late January 2026
House passed $1.2T spending bill (340-88) including PRV renewal.
February 3, 2026
Signed into law. Consolidated Appropriations Act, 2026 extends RPD PRV program through September 30, 2029. GAO study mandated.
Abolishment Risk: 2026-2029
LOW
Bipartisan reauthorization just enacted
House vote: 340-88
Abolishment Risk: Post-2029
MODERATE
Depends on GAO study outcomes
CNPV as potential replacement
Recent PRV Sales (2022-2025)
Date Seller Drug / Disease Buyer Type Price ($M)
Nov 2022 Bluebird Bio Zynteglo / Beta-thalassemia Bristol Myers Squibb RPD $95
Jan 2023 Bluebird Bio Skysona / CALD Argenx SE RPD $102
Jul 2023 Sarepta Therapeutics Elevidys / Duchenne MD Undisclosed RPD $102
Feb 2024 Valneva Ixchiq / Chikungunya Undisclosed TD $103
Aug 2024 Ipsen Sohonos / FOP Large global pharma RPD $158
Nov 2024 Acadia Pharma DAYBUE / Rett Syndrome Undisclosed RPD $150
Nov 2024 PTC Therapeutics KEBILIDI / AADC Deficiency Undisclosed RPD $150
Feb 2025 Zevra Therapeutics MIPLYFFA / Niemann-Pick C Undisclosed RPD $150
May 2025 Abeona Therapeutics Zevaskyn / Epidermolysis Bullosa Undisclosed RPD $155
Jun 2025 Bavarian Nordic Vimkunya / Chikungunya Undisclosed TD $160
Sources: Duke PRV Database, BioSpace, Fierce Pharma, BioPharma Dive, GAO, Spencer Fane, FDA Law Blog · Research compiled March 2026